Senators Oppose Patent Reform Provisions; GSK Also Urges Revisions To Bill
This article was originally published in The Tan Sheet
Executive Summary
As patent reform legislation heads toward the Senate floor, members of the biotech and pharmaceutical industries are imploring legislators to alter key provisions. And a group of Senators is criticizing the bill's formulation for apportioning damage awards in infringement suits
You may also be interested in...
Kyl’s Patent Reform Bill Gains Acceptance From Drug And Biotech Industries
Sen. Jon Kyl plans to take up the patent reform legislation battle in the next Congress after the Senate deadlocked on Judiciary Committee Chairman Patrick Leahy's proposal
Kyl’s Patent Reform Bill Gains Acceptance From Drug And Biotech Industries
Sen. Jon Kyl plans to take up the patent reform legislation battle in the next Congress after the Senate deadlocked on Judiciary Committee Chairman Patrick Leahy's proposal
Kyl’s Patent Reform Bill Gains Acceptance From Drug And Biotech Industries
Sen. Jon Kyl plans to take up the patent reform legislation battle in the next Congress after the Senate deadlocked on Judiciary Committee Chairman Patrick Leahy's proposal